featured content
The COVID-19 pandemic has made the public savvier about diagnostics, but at which point should the involvement of patients in their own testing be limited?
New regulations, politics, and the economy have transformed the UK's in vitro diagnostic industry the past few years, and more adjustments are on the horizon.
As insurers drive down reimbursements, smaller labs are forced to accept payment rates similar to that of national outfits, but without the advantages of scale.
Climate Change Poses New Challenges for Dx Industry With Potential Emergence of New Diseases
Premium
While many firms have yet to take practical steps dealing with the potential disease implications of climate change, they may soon find they'll have to.
The use of artificial intelligence may still be in its infancy in the Dx space, but some believe the technology can lead to more efficient and precise patient care.